Neuroendocrine tumours (NETs) of the lung arise from bronchial mucosal cells known as enterochromaffin cells or Kulchitsky cells, which are part of the diffuse neuroendocrine system. These tumours account for 20-25 % of all primary lung neoplasms [1] . The pathological spectrum of pulmonary NETs ranges from low-or intermediate-grade neoplasms, also known as typical or atypical bronchial carcinoids (BCs), respectively, to more aggressive tumours such as large cell and small cell lung cancer [1, 2] . In detail, the pathological distinction is substantially based on the microscopic morphology, the grade of differentiation, the mitotic rate and the presence of necrosis [2] .
The distinct features among the different pulmonary NETs include not only their pathological characteristics but also the clinical behaviour, epidemiology, treatment and prognosis [3] . From a clinical point of view, typical BCs are indolent neoplasms with a good prognosis, whereas atypical BCs have a less indolent behaviour with a certain propensity for metastatic spread. Both these well-differentiated pulmonary NETs are optimally treated with complete surgical excision, although some divergent management strategies of care have been recently recommended for typical and atypical BCs [4, 5] . Indeed, while surgical resection remains the gold standard in the treatment of BCs, the extension of parenchymal resection (lobar versus sublobar resection) and the need for a radical lymph node dissection may be influenced by the histological characterization [4, 5] . Conversely, more aggressive pulmonary NETs, such as large cell and small cell lung cancer, often present with local invasion, thoracic lymph node metastases and distant spread; as a result, affected patients may not be candidates for surgical resection, often being treated with chemotherapy with or without radiation therapy, showing a poor prognosis [3, 4] .
Therefore, a correct pathological identification of pulmonary NETs during the preoperative setting is a key element for planning the best strategy of care, considering the different biological behaviour of the various pulmonary NET subtypes. Nevertheless, the preoperative pathology differentiation between typical and atypical BCs frequently appears not accurate. Furthermore, the structural imaging findings are often similar in typical and atypical BCs and, accordingly, a clear differentiation between these pulmonary NETs is not possible through radiological findings only [1] [2] [3] [4] .
Positron emission tomography (PET)/CT with different tracers, such as 18 F-fluorodeoxyglucose (FDG) and somatostatin analogues labelled with 68 Ga ( 68 Ga-somatostatin analogues), may provide useful information for evaluating pulmonary NETs, including BCs [6] .
The diagnostic performance of 18 F-FDG PET/CT has been reported to be superior in more aggressive pulmonary NETs (large cell and small cell lung cancer) compared to BCs, which are usually characterized by low growth [7, 8] . False-positive findings of 18 F-FDG PET/CT due to inflammatory lesions are well known [6] . A recent study reported that atypical BCs usually show a higher 18 F-FDG uptake compared to typical BCs, due to their more aggressive behaviour [9] . Moreover, 18 F-FDG PET/CT may provide useful prognostic information in patients with pulmonary NETs because high maximum standardized uptake values (SUV max ) are associated with short survival and poor prognosis [7] [8] [9] .
Since pulmonary NETs usually present an overexpression of somatostatin receptors on their cell surface, somatostatin receptor imaging has been widely used in the diagnosis, staging and restaging of these tumours [6] . Recently, PET/CT using somatostatin analogues (such as DOTANOC, DOTATOC, DOTATATE) labelled with 68 Ga has been increasingly used in patients with BCs due to its high diagnostic accuracy in NET detection [10] . Some false-negative results of somatostatin receptor PET/CT in pulmonary NETs may be due to tumours with low expression of somatostatin receptors. Conversely, inflammatory lesions may occasionally cause false-positive results due to the high expression of somatostatin receptors on the cell surface of the inflammatory cells [10] . Somatostatin receptor PET/CT has been demonstrated to be superior compared to somatostatin receptor scintigraphy in evaluating lung NETs, due to the superior spatial resolution of PET imaging [6] . Furthermore, 68 Ga-somatostatin analogues provided better results compared to the radiolabelled amino acid 18 Fdihydroxyphenylalanine (DOPA) in evaluating lung NETs [6] , but literature reports specifically addressing the use of 18 F-DOPA in pulmonary NETs are few [11] . Since different information may be obtained using various PET tracers, some authors have recently reported preliminary results on dual-tracer PET/CT imaging using F-FDG PET/CT in differentiating typical and atypical BCs. The overall detection rate of 68 Ga-DOTATOC PET/CT for typical and atypical BCs was 100 and 86 %, respectively, with a median SUV max of 33 and 10.3, respectively. The overall detection rate of 18 F-FDG PET/CT for typical and atypical BCs was 54 and 100 % with a median SUV max of 2.6 and 5.9, respectively [13] .
In a study published in this issue of the European Journal Ga-DOTATOC PET/CT was superior in patients with typical BCs compared to those with atypical BCs (100 versus 80 %, respectively), whereas the sensitivity of 18 F-FDG PET/CT was superior in patients with atypical BCs compared to those with typical BCs (100 versus 61.9 %) [15] .
Overall, based on available literature data, 68 Ga-somatostatin analogues seem to be the PET tracers of choice in the initial evaluation of patients with clinical suspicion of BC. In these patients, in order to detect a BC, PET/CT using 68 Gasomatostatin analogues could be performed primarily and, if negative, 18 F-FDG PET/CT could be performed subsequently. In fact, a negative PET/CT using 68 Ga-somatostatin analogues may substantially rule out the presence of typical BCs, but it seems not sufficient to exclude the presence of atypical BCs (which occasionally may present low uptake of 68 Ga-somatostatin analogues but are often 18 F-FDGavid tumours). The combination of PET/CT using 68 Gasomatostatin analogues and 18 F-FDG seems to be very useful in predicting the histology in patients with clinical suspicion of BCs, allowing a "tailored" therapeutic approach in such patients. Further large prospective studies and cost-effectiveness analyses are needed to validate this diagnostic strategy.
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